bit.bio

The page lists cell products, including human iPSC-derived cells for research, drug discovery, and toxicology.

The page details bit.bio’s CRISPR screening services, including pooled and knockout screens in human iPSC-derived cells.

ioCells are human iPSC-derived cells deterministically programmed at scale to reduce research variability.

Top tips for culturing iPSC-derived microglia

The page describes how iPSC-derived models improve drug discovery through scalable, human-relevant assays.

bit.bio launches the ioScreens platform CRISPR screening service & appoints Sejla Salic-Hainzl as CTO.

Modulate gene activity in human iPSC-derived cells with a set of CRISPR-ready tools for gene knockout, activation, and interference experiments

bit.bio will use Automata to automate a key aspect of its production of iPSC derived human cells

bit.bio CEO spoke about reprogramming human cells at the TEDxCambridgeUniversity ‘Untangling networks’ event.

The page explains bit.bio’s hiring process and candidate criteria.

bit.bio describes its career opportunities in a dynamic work environment.

bit.bio lists open roles for a fast-growing company in biology.

Blog for employee spotlights

Meet Dr Ania Wilczynska, Head of Computational Genomics, Non-Clinical at bit.bio.

Meet Dr Oliver Dovey, Director of the Functional Genomics team at bit.bio.

Meet Kapil Agashi, Senior Patent Attorney at bit.bio.

The page explains bit.bio’s founding, mission, and vision to advance biomedical research and cell therapies using synthetic biology.

bit.bio values diversity and fosters an inclusive work environment to support employee growth.

The page outlines bit.bio’s commitments to social responsibility and sustainability.

bit.bio offers partnering opportunities that affords access to the most relevant wild type iPSC-derived human cells and corresponding disease models

Fill out the form to request an academic quote for bit.bio's ioCells

bit.bio’s opti-ox technology reprograms stem cells into any cell type at scale for research.

The page describes how bit.bio processes personal information for job applicants.

bit.bio outlines its cookies policy for website visitors.

Trade marks owned by Bit Bio Limited in certain jurisdictions

bit.bio introduces **ioAstrocytes 2.0**, an updated human iPSC-derived astrocyte model optimized for reproducible neuronal assays. The refined product supports serum-free, consistent research applications, including studies on seizure risk and neurodegenerative diseases. Researchers can now access a defined system for functional brain network modeling.

Oct 2026bit.bioNews article

bit.bio secures $50 million in Series C funding from M&G Investments to advance its human cell programming platform. The Cambridge-based biotech uses opti-ox technology to produce defined human cells for drug discovery and research applications. These reproducible cell types aim to support pharmaceutical development workflows.

Jan 2026European Biotechnology MagazineNews article

bit.bio secures $50 million in funding to advance its human cell programming technology. The Cambridge, UK-based biotech company applies this approach to develop novel biological solutions. Investors back the company’s potential to transform healthcare through engineered cell therapies.

Jan 2026FinSMEsNews article

bit.bio raises $50 million in Series C funding to develop human cell programming technology for drug discovery. The round is led by M&G Investments, supporting the UK-based company’s innovation in drug development. This technology aims to accelerate the creation of human cells for research and therapeutic applications.

Jan 2026MedPath TrialNews article